Latest Oncolytics Biotech Inc. Stories
CALGARY, Nov. 10 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") today announced its financial results and operational highlights for the quarter ended September 30, 2010. "We are excited to be conducting our first Phase 3 study," said Dr. Brad Thompson, President and CEO of Oncolytics. "Moving into the fourth quarter the Company's fundamentals remain strong and we are well positioned to execute on our clinical strategy in...
CALGARY, Nov. 1 /PRNewswire/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics") today announced that an abstract covering preclinical research with reovirus (REOLYSIN((R))) is available on the European CanCer Organisation (ECCO) website at www.ecco-org.eu. The research is scheduled to be presented at the 22(nd) EORTC-NCI-AACR symposium on Molecular Targets and Cancer Therapeutics being held in Berlin, Germany from November 16(th) - 19(th) 2010. The abstract, entitled...
CALGARY, Oct. 26 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that interim data from a U.K. translational clinical trial (REO 013) investigating intravenous administration of REOLYSIN((R)) in patients with metastatic colorectal cancer prior to surgical resection of liver metastases was presented at the International Symposium on Cytotoxic T-lymphocytes (CTL) and Immunostimulation being held in Pamplona, Spain. The presentation...
CALGARY, Oct. 4 /PRNewswire-FirstCall/ - Dr. Brad Thompson, President and Chief Executive Officer of Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will present a corporate overview of the Company at the 9th Annual BIO Investor Forum on Wednesday, October 6th, 2010 at 8:00 a.m. PDT. The conference takes place on October 5th and 6th at the Palace Hotel in San Francisco, CA. A live audio link to the webcast presentation is available at:...
CALGARY, Sept. 28 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) ("Oncolytics") today announced that it has been granted U.S. Patent, # 7,803,385 entitled "Reoviruses Having Modified Sequences." The patent claims cover methods for making and using modified reoviruses, and pharmaceutical compositions that include modified reoviruses. "This composition of matter patent covers the reovirus variant that Oncolytics is using in its clinical trials with patent protection...
CALGARY, Sept. 27 /PRNewswire-FirstCall/ - Dr. Brad Thompson, President and Chief Executive Officer of Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will present a corporate overview of the Company at the 5th annual JMP Securities Healthcare Conference on Tuesday, September 28th, 2010 at 10:00 a.m. EDT. The conference takes place from September 27th to 28th at the New York Palace Hotel in New York, NY. A live audio link to the webcast presentation is available at:...
CALGARY, Sept. 9 /PRNewswire-FirstCall/ - Mr. Doug Ball, Chief Financial Officer of Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will present a corporate overview of the Company at the Rodman & Renshaw Annual Global Investment Conference on Tuesday, September 14th, 2010 at 10:25 a.m. EDT. The conference takes place from September 12th to 15th at the New York Palace Hotel in New York, NY. A live audio link to the webcast presentation is available at:...
TORONTO, Sept. 2 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that the Gynecologic Oncology Group (GOG) intends to conduct a randomized Phase II trial of weekly paclitaxel versus weekly paclitaxel with REOLYSIN(R) in patients with persistent or recurrent, ovarian, fallopian tube or primary peritoneal cancer (GOG186H). The study has been approved and will be sponsored by the Cancer Therapy Evaluation Program, Division of Cancer...
CALGARY, Aug. 5 /PRNewswire-FirstCall/ - Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will present a corporate overview of the Company at the 30th Annual Canaccord Genuity Growth Conference on Tuesday August 10th, 2010 at 10:30 a.m. EDT. The conference takes place from August 10th - 12th at the InterContinental Hotel in Boston, MA. A live audio link to the webcast presentation is available at: http://www.wsw.com/webcast/canaccord2/oncy/ or on the...
CALGARY, July 29 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") today announced its financial results and operational highlights for the quarter ended June 30, 2010. "We have recently passed a number of key milestones in our clinical program, most notably the opening of enrollment in our Phase 3 head and neck cancer study, the expansion of the study to other jurisdictions internationally, and the reporting of positive results from an...
